Absorption, disposition and pharmacokinetics of solid lipid nanoparticles

Current Drug Metabolism

Volumn 13, Issue 4, 2012, Pages 418-428

  Qi, Jianping ^a   Lu, Yi ^a   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Absorption; Biodistribution; Biopharmaceutics; Disposition; Pharmacokinetics; Solid lipid nanoparticles

Indexed keywords

CELECOXIB; CHYLOMICRON; CYCLOSPORIN A; DIAZEPAM; DOXORUBICIN; DRUG CARRIER; FENOFIBRATE; FLURBIPROFEN; GLYCEROL OLEATE; IDARUBICIN; IDARUBICINOL; INSULIN; LIPOSOME; MEVINOLIN; NANOSTRUCTURED LIPID CARRIER; NITRENDIPINE; PACLITAXEL; PODOPHYLLOTOXIN; POLOXAMER; POLYOXYETHYLENE STEARYL ETHER; POLYSORBATE 80; PREDNICARBATE; RETINOIC ACID; RILUZOLE; SANDIMMUN OPTORAL; SOLID LIPID NANOPARTICLE; SURFACTANT; TOBRAMYCIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINPOCETINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD BRAIN BARRIER; CONVULSION; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; GENETIC TRANSFECTION; HUMAN; LIPID COMPOSITION; LIPOPHILICITY; NONHUMAN; PARTICLE SIZE; RESPIRATORY SYSTEM;

ABSORPTION; ANIMALS; DRUG CARRIERS; HUMANS; LIPIDS; NANOPARTICLES; TISSUE DISTRIBUTION;

EID: 84860640294     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800166526     Document Type: Article

References (160)

1. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50(1), 161-177. (Pubitemid 30326695)
2. Muller, R. H.; Mehnert, W.; Lucks, J. S.; Schwarz, C.; Zurmuhlen, A.; Weyhers, H.; Freitas, C.; Ruhl, D. Solid Lipid Nanoparticles (Sln) - an Alternative Colloidal Carrier System for Controlled Drug-Delivery. Eur. J. Pharm. Biopharm., 1995, 41(1), 62-69.
3. Wissing, S. A.; Kayser, O.; Muller, R. H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev., 2004, 56(9), 1257-1272. (Pubitemid 38510473)
4. Jenning, V.; Gysler, A.; Schafer-Korting, M.; Gohla, S. H. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm., 2000, 49(3), 211-218. (Pubitemid 30229868)
5. Souto, E. B.; Muller, R. H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol., 2009, 197(2), 115-141.
6. Sawant, K. K.; Dodiya, S. S. Recent advances and patents on solid lipid nanoparticles. Recent Pat. Drug Deliv. Formul., 2008, 2(2), 120-135.
7. Muller, R. H.; Radtke, M.; Wissing, S. A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev., 2002, 54 Suppl 1, S131-155. (Pubitemid 35379959)
8. Seyfoddin, A.; Shaw, J.; Al-Kassas, R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv., 2010, 17(7), 467-489.
9. Bi, R.; Shao, W.; Wang, Q.; Zhang, N. Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. J. Biomed. Nanotechnol., 2009, 5(1), 84-92.
10. Kang, K. C.; Jeong, N. H.; Lee, C. I.; Pyo, H. B. Preparation and characterization of SLNs (W/O/W type) contained lipoic acid PEG ester by variation lipid. J. Ind. Eng. Chem., 2009, 15(4), 529-536.
11. Freitas, C.; Muller, R. H. Correlation between long-term stability of solid lipid nanoparticles (SLN (TM)) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 1999, 47(2), 125-132. (Pubitemid 29185115)
12. Mehnert, W.; Mader, K. Solid lipid nanoparticles - Production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47(2-3), 165-196. (Pubitemid 32324113)
13. zur Muhlen, A.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery drug release and release mechanism. Eur. J. Pharm. Biopharm., 1998, 45(2), 149-155. (Pubitemid 28167741)
14. Hu, F. Q.; Yuan, H.; Zhang, H. H.; Fang, M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm., 2002, 239(1-2), 121-128. (Pubitemid 34615801)
15. Souto, E. B.; Muller, R. H. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J. Microencapsul., 2006, 23(4), 377-388. (Pubitemid 44132547)
16. Yuan, H.; Wang, L. L.; Du, Y. Z.; You, J.; Hu, F. Q.; Zeng, S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloid Surface B, 2007, 60(2), 174-179. (Pubitemid 350030429)
17. Bunjes, H. Lipid nanoparticles for the delivery of poorly watersoluble drugs. J. Pharm. Pharmacol., 2010, 62(11), 1637-1645.
18. Bunjes, H.; Unruh, T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv. Drug Deliv. Rev., 2007, 59(6), 379-402. (Pubitemid 47259221)
19. Radomska-Soukharev, A. Stability of lipid excipients in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59(6), 411-418. (Pubitemid 47259223)
20. Yang, L.; Geng, Y.; Li, H.; Zhang, Y.; You, J.; Chang, Y. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie., 2009, 64(2), 86-89.
21. Sarmento, B.; Martins, S.; Ferreira, D.; Souto, E. B. Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomedicine, 2007, 2(4), 743-749.
22. Chen, Y.; Dalwadi, G.; Benson, H. A. Drug delivery across the blood-brain barrier. Curr. Drug Deliv., 2004, 1(4), 361-376.
23. Lockman, P. R.; Oyewumi, M. O.; Koziara, J. M.; Roder, K. E.; Mumper, R. J.; Allen, D. D. Brain uptake of thiamine-coated nanoparticles. J. Control. Release, 2003, 93(3), 271-282. (Pubitemid 37485949)
24. Liu, Z.; Zhong, Z.; Peng, G.; Wang, S.; Du, X.; Yan, D.; Zhang, Z.; He, Q.; Liu, J. Folate receptor mediated intracellular gene delivery using the charge changing solid lipid nanoparticles. Drug Deliv., 2009, 16(6), 341-347.
25. Muller, R. H.; Radtke, M.; Wissing, S. A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm., 2002, 242(1-2), 121-128.
26. Jenning, V.; Thunemann, A. F.; Gohla, S. H. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm., 2000, 199(2), 167-177. (Pubitemid 30236188)
27. Almeida, A. J.; Runge, S.; Muller, R. H. Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters. Int. J. Pharm., 1997, 149(2), 255-265. (Pubitemid 27193412)
28. Olbrich, C.; Gessner, A.; Kayser, O.; Muller, R. H. Lipid-drugconjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target., 2002, 10(5), 387-396.
29. Radornska-Soukharev, A. Stability of lipid exciplents in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59(6), 411-418.
30. Bondi, M. L.; Montana, G.; Craparo, E. F.; Picone, P.; Capuano, G.; Di Carlo, M.; Giammona, G. Ferulic Acid-Loaded Lipid Nanostructures as Drug Delivery Systems for Alzheimer's Disease: Preparation, Characterization and Cytotoxicity Studies. Curr. Nanosci., 2009, 5(1), 26-32.
31. Mozafari, M. R., ed. Nanocarrier Techonol. : Frontiers Nanother. Solid lipid nanoparticles, ed. A. Saupe and T. Rades. 2006, Springer: Netherlands. 41-50.
32. Liedtke, S.; Wissing, S.; Muller, R. H.; Mader, K. Influence of high pressure homogenisation equipment on nanodispersions characteristics. Int. J. Pharm., 2000, 196(2), 183-185. (Pubitemid 30105739)
33. Igartua, M.; Saulnier, P.; Heurtault, B.; Pech, B.; Proust, J. E.; Pedraz, J. L.; Benoit, J. P. Development and characterization of solid lipid nanoparticles loaded with magnetite. Int. J. Pharm., 2002, 233(1-2), 149-157. (Pubitemid 34230427)
34. Trotta, M.; Debernardi, F.; Caputo, O. Preparation of solid lipid nanoparticles by a solvent emulsitication-diffusion technique. Int. J. Pharm., 2003, 257(1-2), 153-160. (Pubitemid 36507041)
35. Ugazio, E.; Cavalli, R.; Gasco, M. R. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm., 2002, 241(2), 341-344. (Pubitemid 34718035)
36. Gohla, S. H.; Dingler, A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN (TM)). Pharmazie, 2001, 56(1), 61- 63. (Pubitemid 32099544)
37. Marengo, E.; Cavalli, R.; Caputo, O.; Rodriguez, L.; Gasco, M. R. Scale-up of the preparation process of solid lipid nanospheres. Part I. Int. J. Pharm., 2000, 205(1-2), 3-13.
38. Lukowski, G.; Werner, U. Investigation of surface and drug release of solid lipid nanoparticles loaded with acyclovir. Inter. Symp. Control. Rel. Bioact. Mater., 1998, 25, 425-428.
39. Souto, E. B.; Wissing, S. A.; Barbosa, C. M.; Muller, R. H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm., 2004, 278(1), 71-77. (Pubitemid 38670438)
40. Westesen, K.; Bunjes, H.; Koch, M. H. J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release, 1997, 48(2-3), 223-236. (Pubitemid 27401980)
41. zurMuhlen, Z.; zurMuhlen, E.; Niehus, H.; Mehnert, W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm. Res., 1996, 13(9), 1411-1416. (Pubitemid 26344991)
42. Bunjes, H.; Westesen, K.; Koch, M. H. J. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm., 1996, 129(1-2), 159-173. (Pubitemid 26098737)
43. Cai, Z.; Wang, Y.; Zhu, L. J.; Liu, Z. Q. Nanocarriers: A General Strategy for Enhancement of Oral Bioavailability of Poorly Absorbed or Pre-Systemically Metabolized Drugs. Curr. Drug Metab., 2010, 11(2), 197-207.
44. Porter, C. J.; Trevaskis, N. L.; Charman, W. N. Lipids and lipidbased formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov., 2007, 6(3), 231-248. (Pubitemid 46344627)
45. Zhuang, C. Y.; Li, N.; Wang, M.; Zhang, X. N.; Pan, W. S.; Peng, J. J.; Pan, Y. S.; Tang, X. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int. J. Pharm., 2010, 394(1-2), 179- 185.
46. Muller, R. H.; Runge, S.; Ravelli, V.; Mehnert, W.; Thunemann, A. F.; Souto, E. B. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm., 2006, 317(1), 82-89. (Pubitemid 43866342)
47. Zhang, Z.; Lv, H.; Zhou, J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Pharmazie, 2009, 64(9), 574-578.
48. Hanafy, A.; Spahn-Langguth, H.; Vergnault, G.; Grenier, P.; Tubic Grozdanis, M.; Lenhardt, T.; Langguth, P. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv. Drug Deliv. Rev., 2007, 59(6), 419-426. (Pubitemid 47260709)
49. Hu, L.; Tang, X.; Cui, F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J. Pharm. Pharmacol., 2004, 56(12), 1527-1535. (Pubitemid 39601993)
50. Palin, K. J.; Wilson, C. G. The effect of different oils on the absorption of probucol in the rat. J. Pharm. Pharmacol., 1984, 36(9), 641-643. (Pubitemid 14068736)
51. Paliwal, R.; Rai, S.; Vaidya, B.; Khatri, K.; Goyal, A. K.; Mishra, N.; Mehta, A.; Vyas, S. P. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine, 2009, 5(2), 184-191.
52. Sanjula, B.; Shah, F. M.; Javed, A.; Alka, A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J. Drug Target., 2009, 17(3), 249-256.
53. Bargoni, A.; Cavalli, R.; Caputo, O.; Fundaro, A.; Gasco, M. R.; Zara, G. P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res., 1998, 15(5), 745-750. (Pubitemid 28275652)
54. Yuan, H.; Chen, J.; Du, Y. Z.; Hu, F. Q.; Zeng, S.; Zhao, H. L. Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf. B Biointerfaces, 2007, 58(2), 157-164. (Pubitemid 46921452)
55. Zhang, N.; Ping, Q.; Huang, G.; Xu, W.; Cheng, Y.; Han, X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm., 2006, 327(1-2), 153-159. (Pubitemid 44667334)
56. Sachs-Barrable, K.; Thamboo, A.; Lee, S. D.; Wasan, K. M. Lipid Excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of Rhodamine 123 partially due to modifying Pglycoprotein protein expression within Caco-2 Cells. J. Pharm. Pharm. Sci., 2007, 10(3), 319-331. (Pubitemid 350055592)
57. Buszello, K.; Harnisch, S.; Muller, R. H.; Muller, B. W. The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with solutol HS 15. Eur. J. Pharm. Biopharm., 2000, 49(2), 143-149. (Pubitemid 30126062)
58. Shono, Y.; Nishihara, H.; Matsuda, Y.; Furukawa, S.; Okada, N.; Fujita, T.; Yamamoto, A. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci., 2004, 93(4), 877-885. (Pubitemid 38420399)
59. Bhaskar, K.; Anbu, J.; Ravichandiran, V.; Venkateswarlu, V.; Rao, Y. M. Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis., 2009, 8, 6.
60. Wissing, S. A.; Muller, R. H. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity-in vivo study. Eur. J. Pharm. Biopharm., 2003, 56(1), 67-72. (Pubitemid 36802049)
61. Shah, K. A.; Date, A. A.; Joshi, M. D.; Patravale, V. B. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int. J. Pharm., 2007, 345(1-2), 163-171. (Pubitemid 350087549)
62. Bhaskar, K.; Krishna Mohan, C.; Lingam, M.; Prabhakar Reddy, V.; Venkateswarlu, V.; Madhusudan Rao, Y. Development of nitrendipine controlled release formulations based on SLN and NLC for topical delivery: in vitro and ex vivo characterization. Drug Dev. Ind. Pharm., 2008, 34(7), 719-725. (Pubitemid 351962344)
63. Kuntsche, J.; Bunjes, H.; Fahr, A.; Pappinen, S.; Ronkko, S.; Suhonen, M.; Urtti, A. Interaction of lipid nanoparticles with human epidermis and an organotypic cell culture model. Int. J. Pharm., 2008, 354(1-2), 180-195. (Pubitemid 351400323)
64. de Vringer, T.; de Ronde, H. A. Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J. Pharm. Sci., 1995, 84(4), 466-472.
65. Cevc, G. Lipid vesicles and other colloids as drug carriers on the skin. Adv. Drug Deliv. Rev., 2004, 56(5), 675-711. (Pubitemid 38326939)
66. Schafer-Korting, M.; Mehnert, W.; Korting, H. C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv. Drug Deliv. Rev., 2007, 59(6), 427-443. (Pubitemid 47259224)
67. Fang, J. Y.; Fang, C. L.; Liu, C. H.; Su, Y. H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm., 2008, 70(2), 633-640.
68. Bhalekar, M. R.; Pokharkar, V.; Madgulkar, A.; Patil, N.; Patil, N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech, 2009, 10(1), 289-296.
69. Mei, Z.; Wu, Q.; Hu, S.; Li, X.; Yang, X. Triptolide loaded solid lipid nanoparticle hydrogel for topical application. Drug Dev. Ind. Pharm., 2005, 31(2), 161-168. (Pubitemid 40315711)
70. Zhao, Y. J.; Moddaresi, M.; Jones, S. A.; Brown, M. B. A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ. Eur. J. Pharm. Biopharm., 2009, 72(3), 521-528.
71. Souto, E. B.; Doktorovova, S.; Gonzalez-Mira, E.; Egea, M. A.; Garcia, M. L. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr. Eye Res., 2010, 35(7), 537-552.
72. Journal Of Controlled Release Barar, J.; Javadzadeh, A. R.; Omidi, Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin. Drug Deliv., 2008, 5(5), 567-581. (Pubitemid 351877434)
73. Araujo, J.; Gonzalez, E.; Egea, M. A.; Garcia, M. L.; Souto, E. B. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine, 2009, 5(4), 394-401.
74. Liu, Z.; Li, J.; Nie, S.; Guo, H.; Pan, W. Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes. J. Pharm. Pharmacol., 2006, 58(1), 45-50. (Pubitemid 43041995)
75. Li, X.; Nie, S. F.; Kong, J.; Li, N.; Ju, C. Y.; Pan, W. S. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm., 2008, 363(1-2), 177- 182.
76. Shen, J.; Sun, M.; Ping, Q.; Ying, Z.; Liu, W. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology, 2010, 21(2), 025101.
77. Gokce, E. H.; Sandri, G.; Egrilmez, S.; Bonferoni, M. C.; Guneri, T.; Caramella, C. Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr. Eye Res., 2009, 34(11), 996-1003.
78. Attama, A. A.; Reichl, S.; Muller-Goymann, C. C. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int. J. Pharm., 2008, 355(1-2), 307-313.
79. Attama, A. A.; Reichl, S.; Muller-Goymann, C. C. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr. Eye Res., 2009, 34(8), 698-705.
80. Shen, J.; Wang, Y.; Ping, Q. N.; Xiao, Y. Y.; Huang, X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J. Control. Release, 2009, 137(3-4), 217-223.
81. Li, Y. Z.; Sun, X.; Gong, T.; Liu, J.; Zuo, J.; Zhang, Z. R. Inhalable microparticles as carriers for pulmonary delivery of thymopentinloaded solid lipid nanoparticles. Pharm. Res., 2010, 27(9), 1977- 1986.
82. Banker, G. S.; Rhodes, C. T., eds. Modern Pharmaceutics. Fourth ed. 2002, Marcel Dekker, Inc: New York.
83. Pandey, R.; Khuller, G. K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb), 2005, 85(4), 227-234. (Pubitemid 40805619)
84. Liu, J.; Gong, T.; Fu, H.; Wang, C.; Wang, X.; Chen, Q.; Zhang, Q.; He, Q.; Zhang, Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int. J. Pharm., 2008, 356(1-2), 333-344.
85. Pison, U.; Welte, T.; Giersig, M.; Groneberg, D. A. Nanomedicine for respiratory diseases. Eur. J. Pharmacol., 2006, 533(1-3), 341- 350. (Pubitemid 43340025)
86. Ku, T.; Gill, S.; Lobenberg, R.; Azarmi, S.; Roa, W.; Prenner, E. J. Size dependent interactions of nanoparticles with lung surfactant model systems and the significant impact on surface potential. J. Nanosci. Nanotechnol., 2008, 8(6), 2971-2978.
87. Sznitowska, M.; Gajewska, M.; Janicki, S.; Radwanska, A.; Lukowski, G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur. J. Pharm. Biopharm., 2001, 52(2), 159-163. (Pubitemid 32755894)
88. Holpuch, A. S.; Hummel, G. J.; Tong, M.; Seghi, G. A.; Pei, P.; Ma, P.; Mumper, R. J.; Mallery, S. R. Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm. Res., 2010, 27(7), 1224-1236.
89. Olbrich, C.; Bakowsky, U.; Lehr, C. M.; Muller, R. H.; Kneuer, C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control. Release, 2001, 77(3), 345-355. (Pubitemid 33145485)
90. Bondi, M. L.; Azzolina, A.; Craparo, E. F.; Lampiasi, N.; Capuano, G.; Giammona, G.; Cervello, M. Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J. Drug Target., 2007, 15(4), 295-301. (Pubitemid 47161496)
91. Montana, G.; Bondi, M. L.; Carrotta, R.; Picone, P.; Craparo, E. F.; San Biagio, P. L.; Giammona, G.; Di Carlo, M. Employment of cationic solid-lipid nanoparticles as RNA carriers. Bioconjug Chem, 2007, 18(2), 302-308. (Pubitemid 46493499)
92. del Pozo-Rodriguez, A.; Delgado, D.; Solinis, M. A.; Pedraz, J. L.; Echevarria, E.; Rodriguez, J. M.; Gascon, A. R. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int. J. Pharm., 2009, 385(1-2), 157-162.
93. del Pozo-Rodriguez, A.; Delgado, D.; Solinis, M. A.; Gascon, A. R.; Pedraz, J. L. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int. J. Pharm., 2007, 339(1-2), 261-268. (Pubitemid 46977611)
94. Tabatt, K.; Sameti, M.; Olbrich, C.; Muller, R. H.; Lehr, C. M. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle- mediated gene transfer. Eur. J. Pharm. Biopharm., 2004, 57(2), 155-162. (Pubitemid 38283690)
95. Tabatt, K.; Kneuer, C.; Sameti, M.; Olbrich, C.; Muller, R. H.; Lehr, C. M.; Bakowsky, U. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J. Control. Release, 2004, 97(2), 321-332. (Pubitemid 38759489)
96. Du, B.; Yan, Y.; Li, Y.; Wang, S.; Zhang, Z. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles. Pharm. Dev. Technol., 2009, 15(4), 346-353.
97. Tian, J.; Pang, X.; Yu, K.; Liu, L.; Zhou, J. Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin. Pharmazie, 2008, 63(8), 593-597.
98. Zhang, X. X.; Gan, Y.; Gan, L.; Nie, S. F.; Pan, W. S. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J. Pharm. Pharmacol., 2008, 60(8), 1077-1087.
99. Wang, W.; Zhao, X.; Hu, H.; Chen, D.; Gu, J.; Deng, Y.; Sun, J. Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability. Drug Deliv., 2010, 17(3), 114-122.
100. Lu, W.; He, L. C.; Wang, C. H.; Li, Y. H.; Zhang, S. Q. The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice. Int. J. Biol. Macromol., 2008, 43(3), 320-324.
101. Lian, J.; Zhang, S.; Wang, J.; Fang, K.; Zhang, Y.; Hao, Y. Novel galactosylated SLN for hepatocyte-selective targeting of floxuridinyl diacetate. J. Drug Target., 2008, 16(3), 250-256. (Pubitemid 351460654)
102. Yu, W.; Liu, C.; Liu, Y.; Zhang, N.; Xu, W. Mannan-Modified Solid Lipid Nanoparticles for Targeted Gene Delivery to Alveolar Macrophages. Pharm. Res., 2010, 27(8), 1584-1596.
103. Gupta, Y.; Jain, A.; Jain, S. K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol., 2007, 59(7), 935-940. (Pubitemid 47051073)
104. Scholer, N.; Hahn, H.; Muller, R. H.; Liesenfeld, O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm., 2002, 231(2), 167-176. (Pubitemid 34033676)
105. Scholer, N.; Olbrich, C.; Tabatt, K.; Muller, R. H.; Hahn, H.; Liesenfeld, O. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int. J. Pharm., 2001, 221(1-2), 57-67. (Pubitemid 32524035)
106. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J. P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials., 2006, 27(24), 4356-4373. (Pubitemid 43674179)
107. Wang, Y.; Wu, W. In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv., 2006, 13(3), 189-192.
108. Li, S. D.; Huang, L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta, 2009, 1788(10), 2259-2266.
109. Kaur, I. P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release, 2008, 127(2), 97-109.
110. Joshi, M. D.; Muller, R. H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm., 2009, 71(2), 161- 172.
111. Bondi, M. L.; Craparo, E. F.; Giammona, G.; Drago, F. Braintargeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine (Lond), 2010, 5(1), 25-32.
112. Kuo, Y. C.; Su, F. L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate- sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm., 2007, 340(1-2), 143-152.
113. Yang, S. C.; Lu, L. F.; Cai, Y.; Zhu, J. B.; Liang, B. W.; Yang, C. Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control .Release, 1999, 59(3), 299-307. (Pubitemid 29238174)
114. Goppert, T. M.; Muller, R. H. Plasma protein adsorption of Tween 80- and poloxamer 188-stabilized solid lipid nanoparticles. J. Drug Target., 2003, 11(4), 225-231. (Pubitemid 37361968)
115. Musteata, F. M.; Pawliszyn, J.; Qian, M. G.; Wu, J. T.; Miwa, G. T. Determination of drug plasma protein binding by solid phase microextraction. J. Pharm. Sci., 2006, 95(8), 1712-1722. (Pubitemid 44229578)
116. Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev., 2009, 61(6), 428-437.
117. Goppert, T. M.; Muller, R. H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target., 2005, 13(3), 179-187. (Pubitemid 40668171)
118. Yang, S. C.; Zhu, J. B.; Lu, Y.; Liang, B. W.; Yang, C. Z. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res., 1999, 16(5), 751-757. (Pubitemid 29227107)
119. He, J.; Hou, S. X.; Lu, W. G.; Zhu, L.; Feng, J. F. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J. Biomed. Nanotechnol., 2007, 3(2), 195-202. (Pubitemid 351877170)
120. Manjunath, K.; Venkateswarlu, V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Drug Target., 2006, 14(9), 632-645. (Pubitemid 44712359)
121. Bummer, P. M. Physical chemical considerations of lipid-based oral drug delivery - Solid lipid nanoparticles. Crit. Rev. Ther. Drug, 2004, 21(1), 1-19. (Pubitemid 41647585)
122. Bargoni, A.; Cavalli, R.; Zara, G. P.; Fundaro, A.; Caputo, O.; Gasco, M. R. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II-tissue distribution. Pharmacol. Res., 2001, 43(5), 497- 502. (Pubitemid 32578867)
123. Zara, G. P.; Bargoni, A.; Cavalli, R.; Fundaro, A.; Vighetto, D.; Gasco, M. R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci., 2002, 91(5), 1324-1333. (Pubitemid 34651194)
124. Cavalli, R.; Bargoni, A.; Podio, V.; Muntoni, E.; Zara, G. P.; Gasco, M. R. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci., 2003, 92(5), 1085-1094. (Pubitemid 36523455)
125. Joo, H. H.; Lee, H. Y.; Kim, J. C. Stability, Release Property and Skin Penetration of Stearic Acid Nanoparticles. Mol. Cryst. Liq. Cryst., 2009, 508, 137-149.
126. Chen, H.; Chang, X.; Du, D.; Liu, W.; Liu, J.; Weng, T.; Yang, Y.; Xu, H.; Yang, X. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J. Control. Release, 2006, 110(2), 296-306. (Pubitemid 41827483)
127. Santos Maia, C.; Mehnert, W.; Schaller, M.; Korting, H. C.; Gysler, A.; Haberland, A.; Schafer-Korting, M. Drug targeting by solid lipid nanoparticles for dermal use. J. Drug Target., 2002, 10(6), 489-495. (Pubitemid 35230199)
128. Lombardi Borgia, S.; Regehly, M.; Sivaramakrishnan, R.; Mehnert, W.; Korting, H. C.; Danker, K.; Roder, B.; Kramer, K. D.; Schafer- Korting, M. Lipid nanoparticles for skin penetration enhancementcorrelation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Release, 2005, 110(1), 151-163. (Pubitemid 41713939)
129. Teeranachaideekul, V.; Boonme, P.; Souto, E. B.; Muller, R. H.; Junyaprasert, V. B. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. J. Control. Release, 2008, 128(2), 134-141.
130. Yang, W.; Peters, J. I.; Williams, R. O. Inhaled nanoparticles - A current review. Int. J. Pharm., 2008, 356(1-2), 239-247.
131. Courrier, H. M.; Butz, N.; Vandamme, T. F. Pulmonary drug delivery systems: recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst., 2002, 19(4-5), 425-498. (Pubitemid 36314479)
132. Videira, M. A.; Botelho, M. F.; Santos, A. C.; Gouveia, L. F.; de Lima, J. J.; Almeida, A. J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target., 2002, 10(8), 607-613. (Pubitemid 36124361)
133. Muller, R. H.; Ruhl, D.; Runge, S. A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm., 1996, 144(1), 115-121. (Pubitemid 27039349)
134. Olbrich, C.; Muller, R. H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm., 1999, 180(1), 31- 39. (Pubitemid 29131440)
135. Olbrich, C.; Kayser, O.; Muller, R. H. Enzymatic degradation of Dynasan 114 SLN - effect of surfactants and particle size. J. Nanopart. Res., 2002, 4(1-2), 121-129. (Pubitemid 135713409)
136. Olbrich, C.; Kayser, O.; Muller, R. H. Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN)-effect of surfactants, storage time and crystallinity. Int. J. Pharm., 2002, 237(1-2), 119-128. (Pubitemid 34310485)
137. Almeida, A. J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev., 2007, 59(6), 478-490. (Pubitemid 47260710)
138. Varshosaz, J.; Minayian, M.; Moazen, E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J. Liposome Res., 2010, 20(2), 115-123.
139. Hu, L.; Xing, Q.; Meng, J.; Shang, C. Preparation and Enhanced Oral Bioavailability of Cryptotanshinone-Loaded Solid Lipid Nanoparticles. AAPS PharmSciTech, 2010, 11(2), 582-587.
140. Dong, X.; Mumper, R. J. The metabolism of fatty alcohols in lipid nanoparticles by alcohol dehydrogenase. Drug Dev. Ind. Pharm., 2006, 32(8), 973-980. (Pubitemid 44359759)
141. Urtti, A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev., 2006, 58(11), 1131-1135.
142. Gaudana, R.; Jwala, J.; Boddu, S. H.; Mitra, A. K. Recent perspectives in ocular drug delivery. Pharm. Res., 2009, 26(5), 1197-1216.
143. Cavalli, R.; Gasco, M. R.; Chetoni, P.; Burgalassi, S.; Saettone, M. F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int. J. Pharm., 2002, 238(1-2), 241-245. (Pubitemid 34457892)
144. Plumley, C.; Gorman, E. M.; El-Gendy, N.; Bybee, C. R.; Munson, E. J.; Berkland, C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int. J. Pharm., 2009, 369(1- 2), 136-143.
145. Liu, J.; Zhu, J.; Du, Z.; Qin, B. Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles. Drug Dev. Ind. Pharm., 2005, 31(6), 551-556. (Pubitemid 41285733)
146. Li, X.; Wang, D.; Zhang, J.; Pan, W. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers. J. Pharm. Pharmacol., 2009, 61(11), 1485-1492.
147. Sharma, P.; Ganta, S.; Denny, W. A.; Garg, S. Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: Chlorambucil. Int. J. Pharm., 2009, 367(1-2), 187-194.
148. Zara, G. P.; Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M. R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target., 2002, 10(4), 327-335. (Pubitemid 34746314)
149. Zara, G. P.; Cavalli, R.; Fundaro, A.; Bargoni, A.; Caputo, O.; Gasco, M. R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol. Res., 1999, 40(3), 281- 286. (Pubitemid 29435729)
150. Chen, D. B.; Yang, T. Z.; Lu, W. L.; Zhang, Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. (Tokyo), 2001, 49(11), 1444-1447. (Pubitemid 33043274)
151. Kim, J. K.; Park, J. S.; Kim, C. K. Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. Int. J. Pharm., 2010, 383(1- 2), 209-215.
152. Varshosaz, J.; Tabbakhian, M.; Mohammadi, M. Y. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J. Liposome Res., 2010, 20(4), 286-296.
153. Martins, S.; Silva, A. C.; Ferreira, D. C.; Souto, E. B. Improving oral absorption of Salmon calcitonin by trimyristin lipid nanoparticles. J. Biomed. Nanotechnol., 2009, 5(1), 76-83.
154. Li, H.; Zhao, X.; Ma, Y.; Zhai, G.; Li, L.; Lou, H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control. Release, 2009, 133(3), 238-244.
155. Suresh, G.; Manjunath, K.; Venkateswarlu, V.; Satyanarayana, V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech, 2007, 8(1), 24.
156. Bekerman, T.; Golenser, J.; Domb, A. Cyclosporin nanoparticulate lipospheres for oral administration. J. Pharm. Sci., 2004, 93(5), 1264-1270. (Pubitemid 38529699)
157. Kumar, V. V.; Chandrasekar, D.; Ramakrishna, S.; Kishan, V.; Rao, Y. M.; Diwan, P. V. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int. J. Pharm., 2007, 335(1-2), 167-175. (Pubitemid 46482862)
158. Chen, C. C.; Tsai, T. H.; Huang, Z. R.; Fang, J. Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm., 2010, 74(3), 474- 482.
159. Patlolla, R. R.; Chougule, M.; Patel, A. R.; Jackson, T.; Tata, P. N.; Singh, M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Release, 2010, 144(2), 233-241.
160. Han, C.; Qi, C. M.; Zhao, B. K.; Cao, J.; Xie, S. Y.; Wang, S. L.; Zhou, W. Z. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J. Vet. Pharmacol. Ther., 2009, 32(2), 116-123.